Heard SEC got report from shareholders. The company is not in the shareholders meeting and not in the 10Q to forecast the drug Double sale from 500 million to $1 Billion. We know this DOUBLE sale grow is and will not happen overnight.. It should go 10%,20%...increase by each quarter. So the company may referred as improperly promote its stock through the irregular media.
And if there are more patients as the company claims then Insurance will be even more inclined to remove coverage. Part of the reason they previously allowed coverage in the first place is because there are so few patients.